Alpha Teknova (TKNO) Competitors

$5.41 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$5.30 -0.11 (-2.01%)

As of 07/14/2026 06:45 PM Eastern

TKNO vs. PURR, JBIO, SANA, CGEM, and ORIC

Should you buy Alpha Teknova stock or one of its competitors? MarketBeat compares Alpha Teknova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Teknova include Hyperliquid Strategies (PURR), Jade Biosciences (JBIO), Sana Biotechnology (SANA), Cullinan Therapeutics (CGEM), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.

How does Alpha Teknova compare to Hyperliquid Strategies?

Alpha Teknova (NASDAQ:TKNO) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Alpha Teknova presently has a consensus target price of $8.00, indicating a potential upside of 47.87%. Hyperliquid Strategies has a consensus target price of $12.72, indicating a potential upside of 72.78%. Given Hyperliquid Strategies' stronger consensus rating and higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	7.16	-$17.26M	-$0.32	N/A
Hyperliquid Strategies	$1M	1,063.15	-$16.01M	-$7.37	N/A

In the previous week, Hyperliquid Strategies had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for Hyperliquid Strategies and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Hyperliquid Strategies' score of 0.65 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Hyperliquid Strategies	Positive

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alpha Teknova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Hyperliquid Strategies has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Summary

Hyperliquid Strategies beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.

How does Alpha Teknova compare to Jade Biosciences?

Alpha Teknova (NASDAQ:TKNO) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

13.8% of Alpha Teknova shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alpha Teknova currently has a consensus price target of $8.00, indicating a potential upside of 47.87%. Jade Biosciences has a consensus price target of $51.57, indicating a potential upside of 141.67%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Jade Biosciences	N/A	-51.34%	-47.32%

Alpha Teknova has higher revenue and earnings than Jade Biosciences. Alpha Teknova is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	7.16	-$17.26M	-$0.32	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

In the previous week, Jade Biosciences had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 4 mentions for Jade Biosciences and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Jade Biosciences' score of 1.32 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Jade Biosciences	Positive

Alpha Teknova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Summary

Jade Biosciences beats Alpha Teknova on 9 of the 16 factors compared between the two stocks.

How does Alpha Teknova compare to Sana Biotechnology?

Alpha Teknova (NASDAQ:TKNO) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alpha Teknova has higher revenue and earnings than Sana Biotechnology. Alpha Teknova is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	7.16	-$17.26M	-$0.32	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Alpha Teknova has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.13, meaning that its share price is 113% more volatile than the broader market.

Sana Biotechnology has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Sana Biotechnology	N/A	-108.01%	-40.68%

In the previous week, Sana Biotechnology had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Sana Biotechnology's score of 0.47 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Sana Biotechnology	Neutral

Alpha Teknova presently has a consensus target price of $8.00, suggesting a potential upside of 47.87%. Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 166.11%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sana Biotechnology beats Alpha Teknova on 9 of the 16 factors compared between the two stocks.

How does Alpha Teknova compare to Cullinan Therapeutics?

Alpha Teknova (NASDAQ:TKNO) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Alpha Teknova currently has a consensus price target of $8.00, indicating a potential upside of 47.87%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 80.08%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Alpha Teknova has higher revenue and earnings than Cullinan Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	7.16	-$17.26M	-$0.32	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Alpha Teknova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Cullinan Therapeutics' score of 0.87 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Cullinan Therapeutics	Positive

Cullinan Therapeutics has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Summary

Alpha Teknova beats Cullinan Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Alpha Teknova compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Alpha Teknova has higher revenue and earnings than Oric Pharmaceuticals. Alpha Teknova is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Alpha Teknova	$40.52M	7.16	-$17.26M	-$0.32	N/A

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 4 more articles in the media than Alpha Teknova. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Oric Pharmaceuticals' score of 1.77 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
Oric Pharmaceuticals	Very Positive
Alpha Teknova	Very Positive

Oric Pharmaceuticals presently has a consensus price target of $19.27, indicating a potential upside of 82.68%. Alpha Teknova has a consensus price target of $8.00, indicating a potential upside of 47.87%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oric Pharmaceuticals is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Oric Pharmaceuticals has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Alpha Teknova	-41.07%	-24.32%	-16.34%

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Oric Pharmaceuticals and Alpha Teknova tied by winning 8 of the 16 factors compared between the two stocks.

Get Alpha Teknova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TKNO vs. The Competition

Export

Metric	Alpha Teknova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.05M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-16.91	20.98	27.01	24.38
Price / Sales	7.16	311.10	521.33	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	4.23	8.54	10.95	6.33
Net Income	-$17.26M	$23.83M	$3.59B	$331.02M
7 Day Performance	5.05%	-2.77%	-1.45%	-0.33%
1 Month Performance	30.99%	5.85%	2.78%	-1.29%
1 Year Performance	22.95%	52.15%	28.53%	21.30%

Alpha Teknova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TKNO Alpha Teknova	2.3815 of 5 stars	$5.41 flat	$8.00 +47.9%	+20.5%	$290.05M	$40.52M	N/A	240	Positive News
PURR Hyperliquid Strategies	2.401 of 5 stars	$7.71 -5.8%	$12.72 +65.0%	N/A	$1.11B	$1M	N/A	N/A	Gap Up
JBIO Jade Biosciences	2.4789 of 5 stars	$22.12 -1.5%	$47.13 +113.1%	+137.1%	$1.09B	N/A	N/A	20	News Coverage Positive News
SANA Sana Biotechnology	2.9604 of 5 stars	$3.87 -6.2%	$9.50 +145.8%	-15.4%	$1.09B	N/A	N/A	380	Analyst Upgrade
CGEM Cullinan Therapeutics	2.5895 of 5 stars	$17.76 -2.2%	$32.00 +80.2%	+125.8%	$1.09B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TKNO) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Teknova (TKNO) Competitors

TKNO vs. PURR, JBIO, SANA, CGEM, and ORIC

How does Alpha Teknova compare to Hyperliquid Strategies?

Summary

How does Alpha Teknova compare to Jade Biosciences?

Summary

How does Alpha Teknova compare to Sana Biotechnology?

Summary

How does Alpha Teknova compare to Cullinan Therapeutics?

Summary

How does Alpha Teknova compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO vs. The Competition

Alpha Teknova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Teknova (TKNO) Competitors

TKNO vs. PURR, JBIO, SANA, CGEM, and ORIC

How does Alpha Teknova compare to Hyperliquid Strategies?

Do analysts prefer TKNO or PURR?

Which has stronger valuation and earnings, TKNO or PURR?

Does the media refer more to TKNO or PURR?

Do insiders & institutionals have more ownership in TKNO or PURR?

Which has more risk & volatility, TKNO or PURR?

Is TKNO or PURR more profitable?

Summary

How does Alpha Teknova compare to Jade Biosciences?

Do institutionals and insiders have more ownership in TKNO or JBIO?

Do analysts prefer TKNO or JBIO?

Is TKNO or JBIO more profitable?

Which has better earnings & valuation, TKNO or JBIO?

Does the media refer more to TKNO or JBIO?

Which has more volatility & risk, TKNO or JBIO?

Summary

How does Alpha Teknova compare to Sana Biotechnology?

Do institutionals and insiders hold more shares of TKNO or SANA?

Which has better valuation and earnings, TKNO or SANA?

Which has more risk & volatility, TKNO or SANA?

Is TKNO or SANA more profitable?

Does the media refer more to TKNO or SANA?

Do analysts rate TKNO or SANA?

Summary

How does Alpha Teknova compare to Cullinan Therapeutics?

Do analysts rate TKNO or CGEM?

Which has preferable valuation & earnings, TKNO or CGEM?

Which has more volatility & risk, TKNO or CGEM?

Do insiders and institutionals have more ownership in TKNO or CGEM?

Does the media refer more to TKNO or CGEM?

Is TKNO or CGEM more profitable?

Summary

How does Alpha Teknova compare to Oric Pharmaceuticals?

Which has stronger valuation & earnings, ORIC or TKNO?

Which has more risk and volatility, ORIC or TKNO?

Does the media favor ORIC or TKNO?

Do analysts prefer ORIC or TKNO?

Is ORIC or TKNO more profitable?

Do institutionals and insiders have more ownership in ORIC or TKNO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO vs. The Competition

Alpha Teknova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools